Centessa Pharmaceuticals PLC ADR (CNTA NASDAQ) stock market data APIs
$15.92
0.28(1.8%)
as of January 10, 2025
Centessa Pharmaceuticals PLC ADR Financial Data Overview
Price chart is built with
Anychart
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Prev. Close
15.64
Open
15.92
Volume
443 K
High
15.98
Low
15.265
52 wk Range
6.95-18.97
Market Cap
2 062 M
Shares Outstanding
132 M
Revenue
6 853 K
EPS
-0.37
Beta
1.477
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Centessa Pharmaceuticals PLC ADR data using free add-ons & libraries
Get Centessa Pharmaceuticals PLC ADR Fundamental Data
Centessa Pharmaceuticals PLC ADR Fundamental data includes:
- Net Revenue: 6 853 K
- EBITDA: -161 299 008
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-12
- EPS/Forecast: -0.3875
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Centessa Pharmaceuticals PLC ADR News
New
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View R...
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and...
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
AnaptysBio, Inc. Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB10...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentationat American Society of Hematolo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
